• Home
  • Welcome
  • CAD & Treatments
  • Donation
  • Resources
  • Webinar Resources
  • Register Web Series
  • Latest News & Articles
  • Clinical Trials
  • Specialists
  • Media
  • Our Stories
  • Stay In The Know
  • Medical Advisors
  • Contact Us
  • Privacy & Policies
  • E-Learning Education
  • Rare Disease Day
  • Observational Study
  • New Members
  • More
    • Home
    • Welcome
    • CAD & Treatments
    • Donation
    • Resources
    • Webinar Resources
    • Register Web Series
    • Latest News & Articles
    • Clinical Trials
    • Specialists
    • Media
    • Our Stories
    • Stay In The Know
    • Medical Advisors
    • Contact Us
    • Privacy & Policies
    • E-Learning Education
    • Rare Disease Day
    • Observational Study
    • New Members
  • Home
  • Welcome
  • CAD & Treatments
  • Donation
  • Resources
  • Webinar Resources
  • Register Web Series
  • Latest News & Articles
  • Clinical Trials
  • Specialists
  • Media
  • Our Stories
  • Stay In The Know
  • Medical Advisors
  • Contact Us
  • Privacy & Policies
  • E-Learning Education
  • Rare Disease Day
  • Observational Study
  • New Members

Enjaymo Treatment

Download PDF

Enjaymo

FDA approves Enjaymo™ (sutimlimab-jome), first  treatment for use in patients with cold agglutinin disease. Enjaymo is a humanized monoclonal antibody that is designed to selectively target and inhibit C1s in the classical complement pathway, which is part of the innate immune system.

Find out more

FDA Approves Enjaymo

Download PDF

Copyright © 2025 Cold Agglutinin Disease Foundation - All Rights Reserved.

Privacy & Policies

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept